Home › Funds › PHILADELPHIA TRUST CO › ABT

PHILADELPHIA TRUST CO position in ABT

ABBOTT LABORATORIES · Health Care

PHILADELPHIA TRUST CO reported holding 162,641 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$16.1M, representing 1.12% of its reported portfolio and ranking #24 among its reported holdings. PHILADELPHIA TRUST CO has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)162.64K sh
Reported value held$16.07M
Portfolio Weight1.12%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How PHILADELPHIA TRUST CO's ABT position evolved

PHILADELPHIA TRUST CO first disclosed a stake in ABT in Q3 2023 at 284,764 shares (US$27.6M). The position peaked in Q2 2025 at 266,183 shares, worth US$36.2M. Across 13 filings, PHILADELPHIA TRUST CO increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 162,641 shares valued at US$16.1M — a reduction of -11,103 shares quarter over quarter.. Notable position changes include a 31% trim in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 284.76K $27.58M New
Q4 2023 279.35K $30.75M Reduce
Q1 2024 284.52K $32.34M Add
Q2 2024 287.38K $29.86M Add
Q3 2024 299.25K $34.12M Add
Q4 2024 289.75K $32.77M Reduce
Q1 2025 266.64K $35.37M Reduce
Q2 2025 266.18K $36.20M Hold
Q3 2025 258.70K $34.65M Reduce
Q4 2025 254.98K $31.95M Reduce
Q1 2026 251.11K $25.78M Reduce
Q2 2026 173.74K $15.77M Reduce
Q3 2026 162.64K $16.07M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has PHILADELPHIA TRUST CO held ABT?

PHILADELPHIA TRUST CO has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is PHILADELPHIA TRUST CO's current position in ABT?

As of Q3 2026, PHILADELPHIA TRUST CO holds 162.64K shares of ABT (ABBOTT LABORATORIES), valued at $16.07M, representing 1.12% of its reported portfolio and ranking #24.

Has PHILADELPHIA TRUST CO been buying or selling ABT?

In the latest 13F filing (Q3 2026), PHILADELPHIA TRUST CO reduced its position in ABT. The position peaked in Q2 2025 at 266.18K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.